<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>PRO Alert Digest</title>
  <style>
    body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif; margin: 2rem; color: #222; }
    header { margin-bottom: 2rem; }
    section { margin-bottom: 2rem; background: #f5f5f5; padding: 1rem; border-radius: 0.5rem; }
    section h2 { margin-top: 0; font-size: 1.1rem; color: #333; }
    section ul { margin-bottom: 0; }
    article { margin-bottom: 2rem; }
    article h2 { margin-bottom: 0.5rem; font-size: 1.25rem; }
    article ul { margin-top: 0.5rem; }
    article li b { color: #0066cc; font-weight: bold; }
    .meta { color: #666; font-size: 0.9rem; margin: 0; }
  </style>
</head>
<body>
<header><h1>PRO Alert Digest</h1><p>October 13, 2025</p></header>
<section class="summary">
  <h2>Summary of today's articles</h2>
  <ul>
    <li>67% of patients completed assessments, reducing discontinuation risk by 30%</li>
    <li>3 FDA-approved ATTR-CM therapies now rely on PRO endpoints to demonstrate patient benefit</li>
    <li>67% completion rate achieved with proactive reminders, enhancing data quality</li>
  </ul>
</section>

<section class="insights">
  <h2>ðŸ“Š Cross-Article Insights</h2>
  <ul>
    <li>IMPLEMENTATION PATTERN: 2 articles mention automated reminders as tactical approach</li>
  </ul>
</section>

<article>
  <h2><a href="https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391">Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications</a></h2>
  
  <ul>
<li><b>KEY FINDING:</b> 67% of patients completed assessments, reducing discontinuation risk by 30%.</li>
<li><b>TACTICAL WIN [ROADMAP]:</b> Integrate AI-driven reminders to optimize patient engagement and data quality.</li>
<li><b>MARKET SIGNAL [ðŸŸ¡ NOTABLE]:</b> Growing adoption of PROs in oncology trials as regulatory pressure increases.</li>
<li><b>CONCERN:</b> Self-selection bias may skew results toward healthier patients, impacting clinical validity.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204">Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC</a></h2>
  
  <ul>
<li><b>KEY FINDING:</b> 3 FDA-approved ATTR-CM therapies now rely on PRO endpoints to demonstrate patient benefit.</li>
<li><b>TACTICAL WIN [ROADMAP]:</b> Integrate AI-driven analytics to predict patient adherence and optimize ePRO workflows.</li>
<li><b>MARKET SIGNAL [ðŸ”´ URGENT]:</b> New FDA guidance prioritizes PRO integration in cardiovascular trials by Q1 2025.</li>
<li><b>CONCERN:</b> Self-selection bias could inflate PRO improvements, requiring rigorous study design safeguards.</li>
  </ul>
</article>
<article>
  <h2><a href="https://ascopubs.org/doi/10.1200/OA-25-00051">Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer</a></h2>
  
  <ul>
<li><b>KEY FINDING:</b> 67% completion rate achieved with proactive reminders, enhancing data quality.</li>
<li><b>TACTICAL WIN [SHIP NOW]:</b> Integrate daily push notifications to maintain engagement throughout treatment.</li>
<li><b>MARKET SIGNAL [ðŸŸ¡ NOTABLE]:</b> Growing emphasis on PROs in regulatory guidelines for cancer trials.</li>
<li><b>CONCERN:</b> Self-selection bias may underrepresent severe cases, affecting generalizability.</li>
  </ul>
</article>

</body>
</html>
